Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy-Reference-Cited by-同舟云学术

Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy

Published:2023-12 Issue: Volume: Page:
ISSN:2211-3835
Container-title:Acta Pharmaceutica Sinica B
language:en
Short-container-title:Acta Pharmaceutica Sinica B

Author:

Qian Yuzhen,Sun Yixuan,Shi Peishang,Zhou Xiuman,Zhang Qiongqiong,Dong Qingyu,Jin Shengzhe,Qiu Lu,Niu Xiaoshuang,Zhou Xiaowen,Zhao Wenshan,Wu Yahong,Zhai Wenjie,Gao Yanfeng^ORCID

Publisher

Elsevier BV

Subject

General Pharmacology, Toxicology and Pharmaceutics

Reference59 articles.

1. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors;Hargadon;Int Immunopharm,2018

2. Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms;Kordbacheh;Ann Oncol,2018

3. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions;Yi;Mol Cancer,2022

4. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy;Havel;Nat Rev Cancer,2019

5. Beyond immune checkpoint blockade: emerging immunological strategies;Kubli;Nat Rev Drug Discov,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors;BioDrugs;2024-07-30

2. Deciphering Regulatory T-Cell Dynamics in Cancer Immunotherapy: Mechanisms, Implications, and Therapeutic Innovations;ACS Pharmacology & Translational Science;2024-07-03

3. FGL1 and FGL2: emerging regulators of liver health and disease;Biomarker Research;2024-05-31

4. Immunomodulatory Peptides for Tumor Treatment;Advanced Healthcare Materials;2024-05-04